Stockreport

Structure Therapeutics (GPCR) valuation check after Phase 1 obesity candidate ACCG-2671 enters first-in-human trial [Yahoo! Finance]

Structure Therapeutics Inc. - American Depositary Shares  (GPCR) 
PDF See our latest analysis for Structure Therapeutics. The Phase 1 launch for ACCG-2671 comes after a sharp re-rating in Structure Therapeutics, with an 84 percent 1 mon [Read more]